louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04217824: Comparison of Karydakis and Limberg Flap Treatment of Pilonidal Sinus in Adolescent. a Prospective, Randomised Study
Official title: a Prospective, Randomized, Double-blind Study. comparıson of Karydakis Flap and Limberg Flap Treatment of Pilonidal Sinus in Adolescent. a Prospective, Randomised Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pilonidal Sinus
Postoperative Complications
Keywords: pilonidal sinus
presakral apse
limberg flap
karydakis flap
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2020-01-03
Enrollment: 90
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Pilonidal sinus disease (PSD) is a chronic inflammation and infection of the sacrococcygeal region. Produces clinic findings with abscess and discharge in the sacrococcygeal region or painful sinus tract in the natal cleft. Its incidence rate among Turkish servicemen is reported to be 8.8% in a study. Although pilonidal sinus disease is common in men, this is the opposite in adolescence. Because adolescent girls are 2 or 3 times more.

Karydakis flap and Limberg flap operations widely preferred in recent years in the surgical treatment of PSD. In our study, we aim to compare these two techniques prospectively and randomly.

Detailed description: The best treatment technique for pilonidal sinus disease (PSD) is still controversial. While some researchers prefer minimally invasive methods, some researchers prefer surgical treatment. The most important concern in surgical treatment options is the prolongation of the disease recovery time and recurrence of the disease. Complications that may develop after treatment prolong the treatment period. The aim of this prospective, randomized study was to compare the results of the widely used Limberg and Karydakis flap operations in recent years. The parameters that will be used in the comparison will be an infection, recurrence and wound decomposition.

Eligibility criteria: Inclusion Criteria:

* Pilonidal sinus disease

Exclusion Criteria:

* Other disease than pilonidal sinus disease.

Primary outcomes:
measure: Postoperative recurrence
timeFrame: 1 month
Secondary outcomes:
measure: Postoperative infection
timeFrame: 1 week
measure: Postoperative wound dehiscence
timeFrame: 1 week
Other outcomes:
Locations:
city: Kahramanmaras
country: Turkey
facility: Kahramanmaras Sutcu Imam University
state: Onikisubat
Study officials:
affiliation: kahramanmarasSUI
name: ahmet gökhan güler
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02096224: Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort
Official title: Comparison of the Effects of Sevoflurane and Desflurane on Prevention of Catheter-related Bladder Discomfort
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Catheter Site Discomfort
Complications
Anesthesia
Urinary Bladder Neoplasms
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-03-26
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: We want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of catheter-related bladder discomfort.

Detailed description: The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The volatile anesthetics such as sevoflurane and desflurane are known to block the muscarinic receptor in different ways.

We want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of catheter-related bladder discomfort.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for transurethral bladder excision under general anesthesia
* ASA I-III

Exclusion Criteria:

* Bladder outflow obstruction
* Overactive bladder
* End-stage renal disease
* Neurogenic bladder
* Heart failure
* Arrhythmia
* Morbid obesity
* Use of chronic analgesic medication
* Hepatic disease
* Pulmonary disease
* Psychiatric disease

Primary outcomes:
measure: Catheter-related bladder discomfort
timeFrame: 24 hour postoperatively
Secondary outcomes:
measure: Catheter-related bladder discomfort
timeFrame: 0, 1, 6 and 24 hour postoperatively
measure: Nausea
timeFrame: 0, 1, 6 and 24 hour postoperatively
measure: Vomiting
timeFrame: 0, 1, 6 and 24 hour postoperatively
measure: Dry mouth
timeFrame: 0 houe after admission of operating room
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University of Hospital
Study officials:
affiliation: Seoul National University of Hospital
name: Hee-Pyoung Park, PhD
role: STUDY_CHAIR
References:
citation: Kim HC, Hong WP, Lim YJ, Park HP. The effect of sevoflurane versus desflurane on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of a bladder tumour: a randomized controlled trial. Can J Anaesth. 2016 May;63(5):596-602. doi: 10.1007/s12630-016-0600-7. Epub 2016 Feb 1.
Clinical trial NCT01036724: Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation
Official title: Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Paroxysmal Atrial Fibrillation
Lead sponsor: Biosense Webster, Inc.
Sponsor class: INDUSTRY
First posted: 2009-12-21
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects referred for Radiofrequency ablation treatment for paroxysmal atrial fibrillation.

Brief summary: The purpose of this study is to determine the change in median radiation exposure time and median procedure time following guided radiofrequency (RF) ablation among subjects undergoing treatment for paroxysmal atrial fibrillation with either the CARTO® 3 or the NavX(TM) System.

It is hypothesized that described features will reduce the median radiation exposure during the CARTO® 3 system-guided procedures compared to the NavX(TM) system-guided procedures.


Eligibility criteria: Inclusion Criteria:

* All patients referred for a first radiofrequency ablation procedure for treatment of paroxysmal atrial fibrillation (AF episodes that last less than 30 days and are not terminated via cardioversion) and who are considered eligible for treatment by the physician.

Exclusion Criteria:

* There are no study specific exclusion criteria for this observational study. The exclusion criteria will be conditions that, in the physicians opinion, preclude an RF ablation procedure because the procedure risks outweigh any potential benefits for the subject.

Primary outcomes:
measure: Total Fluoroscopy Time
timeFrame: Throughout the Total Duration of the Procedure
Secondary outcomes:
measure: Total Procedure Time
timeFrame: Total Duration of the Procedure
Other outcomes:
Locations:
city: Victoria
country: Canada
facility: Vancouver Island Health Authority - Royal Jubilee Hospital
state: British Columbia
city: Halifax
country: Canada
facility: QE II Health Sciences Center
state: Nova Scotia
city: London
country: Canada
facility: London Health Sciences
state: Ontario
city: Newmarket
country: Canada
facility: Southlake Regional Healthcare Centre
state: Ontario
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
city: Quebec City
country: Canada
facility: Laval Hopital
state: Quebec
Study officials:
References:
Clinical trial NCT01325324: Comparison of Different Portable Tonometers (Icare Pro, TONO-Pen AVIA, Perkins Tonometer, PASCAL Hand Held Dynamic Contour Tonometer)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Healthy Participants
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2011-03-29
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In different cases intraocular pressure (IOP) have to measured in lying position. Therefore a lot of portable tonometers have been established. The Icare Pro is a new tonometer on the market that allows faster and more comfortable IOP-measurements. No local anesthesia is needed, what is a major advantage for the patients. In this study the investigators want to evaluate if IOP measurements with Icare Pro Tonometer are as reliable as they are with other established portable tonometers (Perkins, TONO-Pen and hand held-Dynamic Contour Tonometer).

* Trial with medical device


Eligibility criteria: Inclusion criteria:

* healthy patients of at least 18 years of age or above

Exclusion criteria:

* diagnosis of glaucoma or other optic neuropathies
* corneal disorder that make IOP measurement impossible

Primary outcomes:
measure: intraocular pressure
timeFrame: Study Visit 1
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Ophthalmic Clinic
state: ZH
Study officials:
affiliation: University Hospital Zurich, Ophtalmic Clinic
name: Jens Funk, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schweier C, Hanson JV, Funk J, Toteberg-Harms M. Repeatability of intraocular pressure measurements with Icare PRO rebound, Tono-Pen AVIA, and Goldmann tonometers in sitting and reclining positions. BMC Ophthalmol. 2013 Sep 5;13:44. doi: 10.1186/1471-2415-13-44.
Clinical trial NCT03638024: Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Official title: Predictive Value of Cell-free Fetal DNA Concentration in the Maternal Plasma for Abnormal Placental Invasion in Cases of Placenta Previa.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Placenta Accreta
Placenta Percreta
Placenta Increta
Placenta Previa
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2018-08-20
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Study group (1): 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).

Brief summary: Cell free fetal DNA might predict abnormal placental invasion

Detailed description: This study aims to evaluate whether measurement of cell-free fetal DNA in the maternal plasma can be predictive of abnormal invasion in cases of placenta previa.

Eligibility criteria: Inclusion criteria:

1. Maternal age range from 20-40 years old.
2. Parity: para 1- para 5.
3. Body mass index range from 18-25 kg/m2.
4. Singleton pregnancy carrying male fetuses.
5. Gestational age range from 28-34 weeks.

Exclusion criteria:

1. Multifetal pregnancy.
2. Hypertension, preterm labor and intrauterine growth restriction.
3. Patients taking a tocolytic agent or those with uterine bleeding at or after blood sampling.

   * Since these complications may increase the level of cell-free fetal DNA.
4. Accidental hemorrhage.

Primary outcomes:
measure: Predictive value of maternal plasma cell free DNA
timeFrame: 4 months
Secondary outcomes:
measure: maternal morbidity
timeFrame: 4 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University, Maternity Hospital
Study officials:
References:
Clinical trial NCT06878924: Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation
Official title: Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atrial Fibrillation (AF)
Keywords: Persistent AF
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation
Sponsor class: OTHER
First posted: 2025-03-17
Enrollment: 162
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Persistent atrial fibrillation

Brief summary: This study is designed to directly compare the safety and efficacy of PFA-based PVI+PWI vs PFA-based PVI+ VoM alcohol ablation in patients with Persistent AF.


Eligibility criteria: Inclusion Criteria:

* Symptomatic persistent AF; 1st or redo ablation with PVI-only in the earlier procedure
* Willing to provide informed consent
* Age: 18-85 years

Exclusion Criteria:

* • Previous PWI or VoM ablation procedure

  * Left ventricular ejection fraction \<40%
  * Left atrial thrombus
  * Myocardial infarction within last 60 days
  * Cardiac surgery in the last 6 months
  * Advanced renal failure
  * Life expectancy \<1 year
  * Pregnant women
  * Unable or unwilling to provide informed consent

Primary outcomes:
measure: Recurrence of atrial arrhythmia: any episode of AF/AT longer than 30 sec off-AAD, after the 2-month blanking period
timeFrame: 1 year
Secondary outcomes:
measure: • Arrhythmia-free on previously ineffective AAD without any dose-escalation
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01054924: Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening
Official title: Clinical Study to Assess the Performance of the Invendo C20 Colonoscope System in Persons Undergoing Colorectal Cancer Screening at Average Risk for CRC
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer Screening
Lead sponsor: Invendo Medical GmbH
Sponsor class: INDUSTRY
First posted: 2010-01-22
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Asymptomatic persons fulfilling U.S. screening criteria for colorectal cancer of age of 50-75 years

Brief summary: The purpose of the study is to evaluate efficacy (i.e. reaching the cecum) and safety of the Invendo C20 Colonoscopy System


Eligibility criteria: Inclusion Criteria:

1. Screenees, i.e. asymptomatic persons willing to undergo screening colonoscopy, at average risk for colorectal cancer
2. Age between 50-75 years
3. Signed informed consent

Exclusion Criteria:

1. Family or personal history of colorectal neoplasia including familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer
2. Prior colonoscopy within preceding 10 years
3. A suspected diagnosis of inflammatory bowel disease, bowel obstruction, acute diverticulitis, known severe diverticulosis or any known large bowel disease
4. Clinically significant cardiovascular or pulmonary diseases
5. Gastrointestinal-tract related symptoms, complaints or diseases suggesting performance of colonoscopy (no screening cases)
6. Cancer or other life threatening diseases or significant chronic conditions
7. Blood clotting disorders and /or anti-coagulant therapy including aspirin within the last 7 days
8. Known pregnancy or positive screening pregnancy tests
9. Previous abdominal surgery except for uncomplicated cholecystectomy, appendectomy or minor pelvic surgery (e.g. hernia repair, oophorectomy)
10. Morbid obesity (BMI \> 40)
11. Clinically significant abnormal screening laboratory findings
12. Clinically significant abnormal screening ECG findings
13. Drug abuse or alcoholism
14. Inability of the screenee to adequately communicate
15. Screenees under custodial care
16. Participation in a clinical study within the last 30 days

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Centrum Gastroenterologie Bethanien
state: Hessen
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf
Study officials:
affiliation: Universitätsklinikum Hamburg-Eppendorf
name: Thomas Roesch, Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Centrum Gastroenterologie Bethanien, Frankfurt
name: Nicolas Hoepffner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Indiana University Hospital
name: Douglas K. Rex, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04636424: Weight Distribution Asymmetry in Relation to Speed During Gait in Children With Spastic Cerebral Palsy.
Official title: Weight Distribution Asymmetry in Relation to Speed During Gait in Children With Spastic Cerebral Palsy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gait, Spastic
Keywords: assymetry-gait-speed-cerebral palsy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 114
Sex: ALL
Minimum age (years): 10
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Background: Improving walking ability is one of the major concerns in therapeutic interventions for children with cerebral palsy.

Aim: determine the relation between the weight distributed on both lower limb and speed during walking.

Detailed description: sixty children with spastic diplegia (group A) and forty-five with hemiparesis ( group B) with age ranged from ten to twelve, they had spasticity grade 1 and 1+ according to modified ashworth scale and they were able to walk with assistance (level II on Gross Motor Classification System).Evaluation was held by the Biodex gait trainer for measuring weight distribution on both lower limbs and speed during gait to determine if there was a relation between weight distribution asymmetry and the speed of gait of those children

Eligibility criteria: Inclusion Criteria:

The selection criteria to the diplegic group were as follows:

1. children diagnosed as spastic diplegia or hemiplegia;
2. the ability to stand independently without support for not less than 30 seconds;
3. the ability to walk independently; a classification of level II in the Gross Motor Function Classification System (GMFCS);
4. and capability to understand simple verbal commands.

Exclusion criteria:

1. Participants were excluded if they were treated for lower limbs orthopedic surgical or with botulinum toxin injection within the last 6 months
2. or if they had fixed lower limb deformity.

Primary outcomes:
measure: speed of gait
timeFrame: 12 weaks
Secondary outcomes:
measure: foot to foot distribution
timeFrame: 12 weaks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Physical Therapy,Cairo University
state: Giza
Study officials:
affiliation: Cairo University
name: Nahla Mohamed
role: STUDY_DIRECTOR
References:
citation: Nahla M. Ibrahim, Mai Elsayed Abbass. EFFECT OF PEDAL TRAINING ON GAIT SPEED IN CHILDREN WITH HEMIPARETIC CEREBRAL PALSY.Int J Physiother Res 2017;5(6):2560-65. ISSN 2321-1822
Clinical trial NCT02668224: Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties.
Official title: Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties : Pilot Study, Interventional, Prospective, Longitudinal.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2016-01-29
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: It is a randomized, controlled clinical trial, in healthy volunteers. They are in two groups : the test one will perform the vibration training (1h of Vibrasens 3 times a week, 24 sessions) whereas the control group will not be training. The primary outcome is the maximal voluntary strength.

Detailed description: These last 10 years, a new idea born: vibrations could have potential effects on muscular reconditioning. Researchers have previously demonstrated the effects on plantar ankle flexion, with the increase of the strength, on healthy volunteers. Nowadays physicians would like to demonstrate the effects on another muscular group: ankle's dorsal flexors. 24 sessions are programmed on 8 weeks.

Moreover, the last results showed a modification of the nervous capacities of the cortical voluntary activation. Transcranial Magnetic Stimulation (TMS) is a great tool to explore the neuromuscular function, at the cortical stage. The use of this tool will allow the characterization the effects of the vibration training on the cortical activation state.

Eligibility criteria: Inclusion Criteria:

* Between 18 and 50 years old
* Both gender
* Occasional sportsman (\<4h/week)
* Affiliated to a social security scheme
* Having freely given their written consent

Exclusion Criteria:

* Taking neuro-active substances able to modify cortico-spinal excitability from Day 10 to the end of the study
* Contraindication to magnetic field application
* Previous pathologies susceptible to modify the process of the tests (particularly stakeholders presenting knee or ankle pathologies)
* Participation during the same time in another interventional experimentation

Primary outcomes:
measure: Increase of maximal voluntary strength in dorsal flexion of the ankle
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: CHU de SAINT-ETIENNE
Study officials:
affiliation: CHU de SAINT-ETIENNE
name: Leonard FEASSON, MD
role: PRINCIPAL_INVESTIGATOR
References: